Spots Global Cancer Trial Database for "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

Official Title: "Principle Test" for Isolation and Characterization of Cancer Cells (CTC)-CXCR4+ Circulating in Belotero Loaded With CXCL12 in Patients With Solid Neoplasms (Endometrium, Kidney, Glioblastoma, Colorectal, Ovary and Lung).

Study ID: NCT05818865

Conditions

Neoplasm Malignant

Interventions

CLG

Study Description

Brief Summary: This is multicentric, interventional, non farmacological and prospective study.

Detailed Description: The new CLG platform, a prototype owned by IRCCS Pascale Institute, is able to reconstruct a PMN for the capture of CTCs able to extravasare and colonize tissues at distance, a fundamental requirement to begin the process of metastasis formation. The purpose of the study is to evaluate in vitro the effectiveness of CLG in the isolation, recovery and subsequent molecular characterization of CTCs from peripheral blood of patients suffering from solid neoplasms (endometrium, kidney, colorectal, glioblastoma and lung).